The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Luca Potestio,Fabrizio Martora,Giuseppe Lauletta,Ylenia Vallone,Teresa Battista,Matteo Megna
DOI: https://doi.org/10.2147/ccid.s462797
2024-04-10
Clinical Cosmetic and Investigational Dermatology
Abstract:Luca Potestio, &ast Fabrizio Martora, &ast Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy &astThese authors contributed equally to this work Correspondence: Luca Potestio, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 - 7462442, Email Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial. Recognizing the pivotal role of this axis has facilitated the development of selective and effective biological drugs, such as anti-IL17 and anti-IL23 monoclonal antibodies. These drugs aim to achieve the complete or near-complete disappearance of psoriatic lesions, as indicated by PASI100 and PASI90 responses, respectively. In this context, the aim of our review was to delve into the functioning of the IL-23/Th17 axis, its dysregulation in psoriasis pathogenesis, and the therapeutic potential of its inhibition. Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have been approved. All these drugs showed high levels of effectiveness in both clinical trials and real-life experiences, with an excellent profile in terms of safety. Certainly, furthers studies will allow for better characterization of biologics' profile, in order to administer the right drug for the right patients at the right moment. Keywords: psoriasis, management, clinical trial, IL-17/23 axis Psoriasis, a chronic-relapsing inflammatory skin condition, affects up to 3% of the general population. 1,2 The prevalence is consistent across genders, displaying a bimodal onset distribution with peaks at 30–39 years and 60–69 years in men, and occurring 10 years earlier in women. 3 Clinically, several phenotypes can be distinguished, with plaque psoriasis as the commonest form (about 90% of cases), characterized by the excessive proliferation and abnormal differentiation of keratinocytes, leading to well-defined erythematous-desquamative plaques covered by whitish or silvery scales, predominantly found on elbows, knees, scalp, and the lumbar area. 1,3 Other phenotypes include guttate, erythrodermic, pustular, inverse, and palmoplantar psoriasis. 1,3,4 Moreover, psoriasis is now considered as a systemic disease, as it is frequently linked to several comorbidities such as psoriatic arthritis, metabolic syndrome, diabetes mellitus, chronic inflammatory bowel disease (IBD), and other systemic diseases. 5,6 Additionally, individuals with psoriasis exhibit elevated rates of depression, anxiety, and neurological disorders, highlighting the significant negative impact on the quality of life of this disease. 7 As regards the etiopathogenesis, multiple factors are involved, including environmental (such as infections, drugs, trauma, and obesity), genetic (up to 40% of psoriasis patients have relatives with the disease), and immunologic elements extensively discussed in the literature. 8 In particular, psoriasis pathogenesis is significantly influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. 8 These triggers set off metabolic processes involving inflammation, cell signalling, immune response dysregulation, and antigen presentation. 9,10 Genome-wide association studies (GWAS) have identified more than 63 susceptibility regions associated with psoriasis in European populations, along with over 20 other loci in the Chinese population. 11 Globally, the formation of psoriatic plaques relies on the intricate interaction between keratinocytes and immune response cells, including T lymphocytes, myeloid and plasmacytoid dendritic cells, macrophages, NK and NK-T cells, granulocytes, mast cells, and innate lymphoid cells. This extensive crosstalk between innate and adaptive immune cells and resident skin cells initiates and sustains a chronic inflammatory state underlying psoriasis. 12 Current pathogenetic models propose that environmental events, such as infection, trauma, or psychological stress, trigger the activation of innat -Abstract Truncated-
dermatology